AbbVie Touts Promising Results For Risankizumab For Ulcerative Colitis Maintenance

AbbVie Inc ABBV announced top-line results from the COMMAND Phase 3 maintenance study, showing risankizumab (Skyrizi) achieved the primary endpoint of clinical remission at week 52, as well as key secondary endpoints in moderately to severely active ulcerative colitis.

A significantly higher proportion of patients who received risankizumab 180 mg or 360 mg achieved clinical remission at week 52: 40% and 38%, respectively, compared to 25% in the induction-only control group.

51% of patients treated with risankizumab 180 mg and 48% treated with risankizumab 360 mg achieved endoscopic improvement at week 52 vs. 32% of patients in the induction-only control group.

Additionally, significantly more patients treated with risankizumab 180 mg and 360 mg achieved histologic endoscopic mucosal improvement at week 52 compared to those treated with induction only: 43% and 42%, respectively, vs. 23%.

A significantly higher proportion of patients who received risankizumab 180 mg or 360 mg achieved steroid-free clinical remission compared to the induction-only control group at week 52 (40% and 37%, respectively, vs. 25%).

Price Action: ABBV shares are down 0.32% at $135.80 on the last check Thursday.